Serum soluble interleukin-2 receptor level at diagnosis predicts transformation in patients with follicular lymphoma

被引：10

作者：

Umino, Kento ^{[1
]}

Fujiwara, Shin-Ichiro ^{[1
]}

Ito, Shoko ^{[1
]}

Mashima, Kiyomi ^{[1
]}

Minakata, Daisuke ^{[1
]}

Nakano, Hirofumi ^{[1
]}

Yamasaki, Ryoko ^{[1
]}

Kawasaki, Yasufumi ^{[1
]}

Sugimoto, Miyuki ^{[1
]}

Ashizawa, Masahiro ^{[1
]}

Hatano, Kaoru ^{[1
]}

Okazuka, Kiyoshi ^{[1
]}

Sato, Kazuya ^{[1
]}

Oh, Iekuni ^{[1
]}

Ohmine, Ken ^{[1
]}

Suzuki, Takahiro ^{[1
]}

Muroi, Kazuo ^{[1
]}

Kanda, Yoshinobu ^{[1
]}

机构：

[1] Jichi Med Univ, Div Hematol, Dept Med, 3311-1 Yakushiji, Shimotuke, Tochigi, Japan

来源：

LEUKEMIA & LYMPHOMA | 2017年 / 58卷 / 02期

关键词：

Follicular lymphoma; soluble interleukin-2 receptor; transformation; B-CELL LYMPHOMA; NON-HODGKINS-LYMPHOMA; PROGNOSTIC INDEX; COMPETING RISK; T-CELLS; SURVIVAL; RITUXIMAB; ERA; EPIDEMIOLOGY; OUTCOMES;

D O I：

10.1080/10428194.2016.1190975

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We evaluated 121 patients with follicular lymphoma (FL) and analyzed the association between the soluble interleukin-2 receptor (sIL-2R) level at diagnosis and the cumulative incidence of transformation. By a receiver-operating characteristic analysis, we determined a cutoff value of sIL-2R for transformation at 4360U/mL to classify patients into two groups. Patients in the high sIL-2R group showed a shorter progression-free survival (PFS) and shorter disease-specific survival (DSS) (p<0.001 and p=0.018). Furthermore, the cumulative incidence of transformation in the high sIL-2R group was higher than that in the low sIL-2R group (40.9% vs. 7.3% at 5 years, p<0.001). In a multivariate analysis, high sIL-2R was an independent predictive risk factor for transformation (HR 7.42, 95% CI: 2.75-20.0, p<0.001). This study showed that the sIL-2R level at diagnosis may be a prognostic factor for transformation, PFS, and DSS in patients with FL.

引用

页码：316 / 323

页数：8

共 32 条

[1] Population-Based Analysis of Incidence and Outcome of Transformed Non-Hodgkin's Lymphoma [J].

Al-Tourah, Abdulwahab J. ;

Gill, Karamjit K. ;

Chhanabhai, Mukesh ;

Hoskins, Paul J. ;

Klasa, Richard J. ;

Savage, Kerry J. ;

Sehn, Laurie H. ;

Shenkier, Tamara N. ;

Gascoyne, Randy D. ;

Connors, Joseph M. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (32) :5165-5169

[2] Rituximab versus a watch-and-wait approach in patients with advanced- stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial [J].

Ardeshna, Kirit M. ;

Qian, Wendi ;

Smith, Paul ;

Braganca, Nivette ;

Lowry, Lisa ;

Patrick, Pip ;

Warden, June ;

Stevens, Lindsey ;

Pocock, Christopher F. E. ;

Miall, Fiona ;

Cunningham, David ;

Davies, John ;

Jack, Andrew ;

Stephens, Richard ;

Walewski, Jan ;

Ferhanoglu, Burhan ;

Bradstock, Ken ;

Linch, David C. .

LANCET ONCOLOGY, 2014, 15 (04) :424-435

[3] Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients [J].

Bastion, Y ;

Sebban, C ;

Berger, F ;

Felman, P ;

Salles, G ;

Dumontet, C ;

Bryon, PA ;

Coiffier, B .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (04) :1587-1594

[4] High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma [J].

Carreras, Joaquim ;

Lopez-Guillermo, Armando ;

Fox, Bridget C. ;

Colomo, Lluis ;

Martinez, Antonio ;

Roncador, Giovanna ;

Montserrat, Emili ;

Campo, Elias ;

Banham, Alison H. .

BLOOD, 2006, 108 (09) :2957-2964

[5] Revised response criteria for malignant lymphoma [J].

Cheson, Bruce D. ;

Pfistner, Beate ;

Juweid, Malik E. ;

Gascoyne, Randy D. ;

Specht, Lena ;

Horning, Sandra J. ;

Coiffier, Bertrand ;

Fisher, Richard I. ;

Hagenbeek, Anton ;

Zucca, Emanuele ;

Rosen, Steven T. ;

Stroobants, Sigrid ;

Lister, T. Andrew ;

Hoppe, Richard T. ;

Dreyling, Martin ;

Tobinai, Kensei ;

Vose, Julie M. ;

Connors, Joseph M. ;

Federico, Massimo ;

Diehl, Volker .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) :579-586

[6] Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy [J].

Ennishi, D. ;

Yokoyama, M. ;

Terui, Y. ;

Asai, H. ;

Sakajiri, S. ;

Mishima, Y. ;

Takahashi, S. ;

Komatsu, H. ;

Ikeda, K. ;

Takeuchi, K. ;

Tanimoto, M. ;

Hatake, K. .

ANNALS OF ONCOLOGY, 2009, 20 (03) :526-533

[7] The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation [J].

Farinha, Pedro ;

Al-Tourah, Abdulwahab ;

Gill, Karamjit ;

Klasa, Richard ;

Connors, Joseph M. ;

Gascoyne, Randy D. .

BLOOD, 2010, 115 (02) :289-295

[8] A proportional hazards model for the subdistribution of a competing risk [J].

Fine, JP ;

Gray, RJ .

JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1999, 94 (446) :496-509

[9] Clinical features of de novo CD25-positive follicular lymphoma [J].

Fujiwara, Shin-ichiro ;

Muroi, Kazuo ;

Tatara, Raine ;

Matsuyama, Tomohiro ;

Ohmine, Ken ;

Suzuki, Takahiro ;

Mori, Masaki ;

Nagai, Tadashi ;

Tanaka, Akira ;

Ozawa, Keiya .

LEUKEMIA & LYMPHOMA, 2014, 55 (02) :307-313

[10] Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index [J].

Goto, H ;

Tsurumi, H ;

Takemura, M ;

Ino-Shimomura, Y ;

Kasahara, S ;

Sawada, M ;

Yamada, T ;

Hara, T ;

Fukuno, K ;

Goto, N ;

Okuno, M ;

Takami, T ;

Seishima, M ;

Moriwaki, H .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2005, 131 (02) :73-79

← 1 2 3 4 →